Benzhexol prevents extrapyramidal symptoms induced by antipsychotics: a randomized controlled study

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000032700

Enrollment

Unknown

Registered

2020-05-07

Start date

2020-06-01

Completion date

Unknown

Last updated

2020-05-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

experimental group:Benzhexol and antipsychotics

control group:Placebo and antipsychotics

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) Patients diagnosed with schizophrenia through the Mini-International Neuropsychiatric Interview (MINI); (2) first-time, drug naive patients; (3) >= 9 years of education; (4) aged 18-65 years.

Exclusion criteria

Exclusion criteria: (1) meets other DSM-5 diagnostic criteria for mental illness, such as depression disorder; (2) has a serious physical illness; (3) is pregnant and breastfeeding; (4) cannot provide informed consent.

Design outcomes

Primary

Measure	Time frame
Extrapyramidal Symptom Rating Scale;	—

Secondary

Measure	Time frame
Brief Psychiatric Rating Scale;Positive and Negative Syndrome Scale;	—

Countries

China

Contacts

Public ContactHuanzhong Liu

Chaohu Hospital, Anhui Medical University

huanzhongliu@126.com+86 13855152219

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026